293 related articles for article (PubMed ID: 8159665)
21. Four crystal structures of the 60 kDa flavoprotein monomer of the sulfite reductase indicate a disordered flavodoxin-like module.
Gruez A; Pignol D; Zeghouf M; Covès J; Fontecave M; Ferrer JL; Fontecilla-Camps JC
J Mol Biol; 2000 May; 299(1):199-212. PubMed ID: 10860732
[TBL] [Abstract][Full Text] [Related]
22. Crystal structure of NADH-dependent ferredoxin reductase component in biphenyl dioxygenase.
Senda T; Yamada T; Sakurai N; Kubota M; Nishizaki T; Masai E; Fukuda M; Mitsuidagger Y
J Mol Biol; 2000 Dec; 304(3):397-410. PubMed ID: 11090282
[TBL] [Abstract][Full Text] [Related]
23. [Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals].
Gutierrez Correa J; Fairlamb AH; Stoppani AO
Rev Argent Microbiol; 2001; 33(1):36-46. PubMed ID: 11407019
[TBL] [Abstract][Full Text] [Related]
24. Crystal structure of putidaredoxin reductase from Pseudomonas putida, the final structural component of the cytochrome P450cam monooxygenase.
Sevrioukova IF; Li H; Poulos TL
J Mol Biol; 2004 Feb; 336(4):889-902. PubMed ID: 15095867
[TBL] [Abstract][Full Text] [Related]
25. Trypanothione reductase from the human parasite Entamoeba histolytica: a new drug target.
Tamayo EM; Iturbe A; Hernández E; Hurtado G; de Lourdes Gutiérrez-X M; Rosales JL; Woolery M; Ondarza RN
Biotechnol Appl Biochem; 2005 Apr; 41(Pt 2):105-15. PubMed ID: 15157186
[TBL] [Abstract][Full Text] [Related]
26. Electron transfer in flavocytochrome P450 BM3: kinetics of flavin reduction and oxidation, the role of cysteine 999, and relationships with mammalian cytochrome P450 reductase.
Roitel O; Scrutton NS; Munro AW
Biochemistry; 2003 Sep; 42(36):10809-21. PubMed ID: 12962506
[TBL] [Abstract][Full Text] [Related]
27. The three-dimensional structure of flavodoxin reductase from Escherichia coli at 1.7 A resolution.
Ingelman M; Bianchi V; Eklund H
J Mol Biol; 1997 Apr; 268(1):147-57. PubMed ID: 9149148
[TBL] [Abstract][Full Text] [Related]
28. Assaying phenothiazine derivatives as trypanothione reductase and glutathione reductase inhibitors by theoretical docking and molecular dynamics studies.
Iribarne F; Paulino M; Aguilera S; Tapia O
J Mol Graph Model; 2009 Nov; 28(4):371-81. PubMed ID: 19801198
[TBL] [Abstract][Full Text] [Related]
29. Kinetic, spectroscopic and thermodynamic characterization of the Mycobacterium tuberculosis adrenodoxin reductase homologue FprA.
McLean KJ; Scrutton NS; Munro AW
Biochem J; 2003 Jun; 372(Pt 2):317-27. PubMed ID: 12614197
[TBL] [Abstract][Full Text] [Related]
30. Peptoid inhibition of trypanothione reductase as a potential antitrypanosomal and antileishmanial drug lead.
Chan C; Yin H; McKie JH; Fairlamb AH; Douglas KT
Amino Acids; 2002 Jun; 22(4):297-308. PubMed ID: 12107758
[TBL] [Abstract][Full Text] [Related]
31. Trypanosoma cruzi topoisomerase II: a target enzyme for the chemotherapy of Chagas' disease? Cloning and characterization of its encoding gene.
Goldenberg S; Fragoso SP; Gonzales-Perdomo M
Biol Res; 1993; 26(1-2):77-80. PubMed ID: 7670549
[TBL] [Abstract][Full Text] [Related]
32. Probing the kinetic mechanism and coenzyme specificity of glutathione reductase from the cyanobacterium Anabaena PCC 7120 by redesign of the pyridine-nucleotide-binding site.
Danielson UH; Jiang F; Hansson LO; Mannervik B
Biochemistry; 1999 Jul; 38(29):9254-63. PubMed ID: 10413499
[TBL] [Abstract][Full Text] [Related]
33. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
Beltran-Hortelano I; Perez-Silanes S; Galiano S
Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design.
Aguirre G; Cabrera E; Cerecetto H; Di Maio R; González M; Seoane G; Duffaut A; Denicola A; Gil MJ; Martínez-Merino V
Eur J Med Chem; 2004 May; 39(5):421-31. PubMed ID: 15110968
[TBL] [Abstract][Full Text] [Related]
35. Novel aryl β-aminocarbonyl derivatives as inhibitors of Trypanosoma cruzi trypanothione reductase: binding mode revised by docking and GRIND2-based 3D-QSAR procedures.
de Paula da Silva CH; Bernardes LS; da Silva VB; Zani CL; Carvalho I
J Biomol Struct Dyn; 2012; 29(6):702-16. PubMed ID: 22546000
[TBL] [Abstract][Full Text] [Related]
36. A 1.4 A crystal structure for the hypoxanthine phosphoribosyltransferase of Trypanosoma cruzi.
Focia PJ; Craig SP; Nieves-Alicea R; Fletterick RJ; Eakin AE
Biochemistry; 1998 Oct; 37(43):15066-75. PubMed ID: 9790669
[TBL] [Abstract][Full Text] [Related]
37. The crystal structure of NADPH:ferredoxin reductase from Azotobacter vinelandii.
Sridhar Prasad G; Kresge N; Muhlberg AB; Shaw A; Jung YS; Burgess BK; Stout CD
Protein Sci; 1998 Dec; 7(12):2541-9. PubMed ID: 9865948
[TBL] [Abstract][Full Text] [Related]
38. Cloning and expression of trypanothione reductase from a New World Leishmania species.
Castro-Pinto DB; Genestra M; Menezes GB; Waghabi M; Gonçalves A; De Nigris Del Cistia C; Sant'Anna CM; Leon LL; Mendonça-Lima L
Arch Microbiol; 2008 Apr; 189(4):375-84. PubMed ID: 18060667
[TBL] [Abstract][Full Text] [Related]
39. Crystal structures of the conserved tRNA-modifying enzyme GidA: implications for its interaction with MnmE and substrate.
Meyer S; Scrima A; Versées W; Wittinghofer A
J Mol Biol; 2008 Jul; 380(3):532-47. PubMed ID: 18565343
[TBL] [Abstract][Full Text] [Related]
40. Three-dimensional structure of the inosine-uridine nucleoside N-ribohydrolase from Crithidia fasciculata.
Degano M; Gopaul DN; Scapin G; Schramm VL; Sacchettini JC
Biochemistry; 1996 May; 35(19):5971-81. PubMed ID: 8634238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
